Collaborative Treatment Considerations for the Optometrist in Relapsed/Refractory Multiple Myeloma: Mitigating and Managing Ocular Adverse Events
The landscape of multiple myeloma treatment is rapidly evolving, and several treatment options are available as front- and subsequent-lines of therapy. Because of the complexity of the treatment landscape and unique toxicities associated with newer BCMA-targeted treatments, education is critical to keep the multiple myeloma treatment team up to date on the most effective approaches to management in order to provide patients with the most appropriate course of therapy. Optometrists serve a critical role in mitigating the ocular side effects associated with the anti-BCMA agents to ensure patients receive optimal treatment for their multiple myeloma.
Optometrists attending local/state association meetings who help manage patients with relapsed/refractory multiple myeloma.
- Review the patient, disease, and treatment factors prescribers consider when managing patients with relapsed/refractory multiple myeloma.
- Discuss the newer BCMA-targeted immunotherapies for relapsed/refractory multiple myeloma, including their mechanism of action and key efficacy and safety data from pivotal clinical trials.
- Discuss common adverse effects seen with recently approved anti-BCMA therapies and explore appropriate monitoring and mitigation strategies to combat these while optimizing therapy.
- Examine synergistic strategies for challenging patient cases using BCMA-targeted immunotherapies, with a focus on optometrist collaborative approaches with the oncologist and others on the patient care team.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from GlaxoSmithKline.
|9:30 AM-9:35 AM||Welcome and Introductions|
|9:35 AM-9:45 AM||Relapsed/Refractory Multiple Myeloma|
|9:45 AM-9:55 AM||How has the Treatment Landscape Changed? Exploring Novel BCMA-targeted Therapies for|
|Relapsed/Refractory Multiple Myeloma|
|9:55 AM-10:25 AM||Ocular Adverse Effects of anti-BCMA Therapy: Case-based Strategies Exploring their|
|Identification, Mitigation, and the Optometrist’s Role|
|10:25 AM-10:30 AM||Conversations with the Expert and Q&A|
Praneetha Thulasi, MD
Section of Cataract, Cornea, External Diseases
Emory Eye Center
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Candice Gillett, MPH–has no relevant financial relationships to disclose in relation to the content of this activity.
Susan Yarborough, CHCP–has no relevant financial relationships to disclose in relation to the content of this activity.
Praneetha Thulasi, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
Scott J. Hershman, MD, FACEHP, CHCP–has no relevant financial relationships to disclose in relation to the content of this activity.
Paul Karpecki, OD, FAAO–has disclosed that he is an advisor or consultant to Alcon, Aldeyra, Allergan/Abbvie, Ametek, Atlas Medical, Avellino Labs, Azura, Bausch + Lomb, BioTissue, Blephex, Bruno Pharmaceuticals, Cambium, Dompe, GoBiquity, Haag Streit, Hilco, iCare USA, Imprimis, Johnson & Johnson Vision, Kala Pharmaceuticals, KEPLR Vision, Kiora Pharmaceuticals, Konan Medical, LenTechs, Neurolens, Novartis, Oasis Medical, Oculus, OcuSoft, Optase, Oyster Point Medical, Rendia, RVL Pharmaceuticals, RxSight, Science Based Health, Sentiss Pharmaceuticals, Sight Sciences, Sun Pharmaceuticals, Surface Pharmaceuticals, Tarsus Medical, Thea, Visant Medical/Stepwise, and Vital Tears. He is also on the speakers bureau for Mallinckrodt and has stock options in Silk Technologies and SleepTite.
Susan H. Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, this activity has been planned and implemented by CME Outfitters, LLC, and Creative Educational Concepts, LLC. CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.